Valeant Pharmaceuticals International announced the U.S. launch of Siliq injection during the American Academy of Dermatology summer meeting, being held July 27-30 in New York.
The FDA approved Siliq (brodalumab) for treating moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy and have failed to respond or have lost response to other systemic therapies in February. It is a monoclonal antibody that targets the IL-17 receptor A.
Siliq has a black box warning for suicidal ideation and behavior risks. The product was approved with a risk evaluation and mitigation strategy involving a one-time enrollment for physicians and one-time informed consent for patients, according to a news release.
Brodalumab is contraindicated in patients with Crohn’s disease. Caution is urged for patients with a chronic infection or a history of recurrent infection, and patients should be evaluated for tuberculosis infection prior to beginning treatment, according to the release.
